http://orcid.org/0000-0002-7762-4052
Citations (43)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Christopher R. McCurdy, Abhisheak Sharma, Kirsten E. Smith, Charles A. Veltri, Stephanie T. Weiss, Charles M. White & Oliver Grundmann. (2024) An update on the clinical pharmacology of kratom: uses, abuse potential, and future considerations. Expert Review of Clinical Pharmacology 17:2, pages 131-142.
Read now
Read now
Kirsten E. Smith, Kelly E. Dunn, David H. Epstein, Jeffrey D. Feldman, Albert Garcia-Romeu, Oliver Grundmann, Jack E. Henningfield, Christopher R. McCurdy, Jeffrey M. Rogers, Destiny Schriefer, Darshan Singh & Stephanie T. Weiss. (2022) Need for clarity and context in case reports on kratom use, assessment, and intervention. Substance Abuse 43:1, pages 1221-1224.
Read now
Read now
Gregory Domnic, Suresh Narayanan, Nethia Mohana-Kumaran & Darshan Singh. (2022) Kratom (Mitragyna speciosa Korth.) an overlooked medicinal plant in Malaysia. Journal of Substance Use 27:1, pages 1-6.
Read now
Read now
Mohammad Farris Iman Leong Bin Abdullah, Novline Yuvashnee & Darshan Singh. (2021) Effect of regular kratom (Mitragyna speciosa Korth.) use on quality of life of people who use kratom. Substance Abuse 42:4, pages 444-449.
Read now
Read now
Ibrahim M. Sablaban & Mohan Gautam. (2020) The diagnosis of severe obsessions in the setting of kratom withdrawal and treatment with lorazepam: Case report. Journal of Addictive Diseases 39:1, pages 138-139.
Read now
Read now
Darshan Singh, Thenmoly Damodaran, Walter C. Prozialeck, Oliver Grundmann, Thiruventhan Karunakaran & B. Vicknasingam. (2019) Constipation prevalence and fatigue severity in regular kratom (Mitragyna speciosa Korth.) users. Journal of Substance Use 24:3, pages 233-239.
Read now
Read now
Articles from other publishers (37)
Jeffrey M. Rogers, Stephanie T. Weiss, David H. Epstein, Oliver Grundmann, Katherine Hill & Kirsten E. Smith. (2024) Kratom addiction per DSM-5 SUD criteria, and kratom physical dependence: Insights from dosing amount versus frequency. Drug and Alcohol Dependence, pages 111329.
Crossref
Crossref
Maximilian Gahr. (2022) Kratom (Mitragyna speciosa): eine psychoaktive Pflanze mit Chancen
und Risiken. Fortschritte der Neurologie · Psychiatrie 91:11, pages 455-465.
Crossref
Crossref
Bin Yang, Shanyong Yi, Ruiling Zhang & Mohammad Farris Iman Leong Abdullah. (2023) Adverse Psychological and Therapeutic Effects of Kratom (Mitragyna speciosa) Use: A Systematic Review. Malaysian Journal of Medicine and Health Sciences 19:5, pages 218-236.
Crossref
Crossref
Jack E. Henningfield, Marek C. Chawarski, Albert Garcia-Romeu, Oliver Grundmann, Norsyifa Harun, Zurina Hassan, Christopher R. McCurdy, Lance R. McMahon, Abhisheak Sharma, Mohammed Shoaib, Darshan Singh, Kirsten E. Smith, Marc T. Swogger, Balasingam Vicknasingam, Zachary Walsh, Daniel W. Wang & Marilyn A. Huestis. (2023) Kratom withdrawal: Discussions and conclusions of a scientific expert forum. Drug and Alcohol Dependence Reports 7, pages 100142.
Crossref
Crossref
Donna Papsun, William SchroederIIII, Justin Brower & Barry Logan. (2023) Forensic Implications of Kratom: Kratom Toxicity, Correlation with Mitragynine Concentrations, and Polypharmacy. Current Addiction Reports 10:2, pages 272-281.
Crossref
Crossref
Elisabeth Prevete, Kim Paula Colette Kuypers, Eef Lien Theunissen, Gianluca Esposito, Johannes Gerardus Ramaekers, Massimo Pasquini & Ornella Corazza. (2023) Clinical Implications of Kratom (Mitragyna speciosa) Use: a Literature Review. Current Addiction Reports 10:2, pages 317-334.
Crossref
Crossref
Kirsten E. Smith, Jeffrey D. Feldman, Destiny Schriefer, Stephanie T. Weiss, Oliver Grundmann, Kelly E. Dunn, Darshan Singh, Christopher R. McCurdy, Gisela Butera & David H. Epstein. (2023) Diagnostic Ambiguities and Underuse of Clinical Assessment Tools: A Systematic Review of Case Reports on Kratom Addiction and Physical Dependence. Current Addiction Reports 10:2, pages 282-292.
Crossref
Crossref
Sushobhan Mukhopadhyay, Sampa Gupta, Jenny L. Wilkerson, Abhisheak Sharma, Lance R. McMahon & Christopher R. McCurdy. (2023) Receptor Selectivity and Therapeutic Potential of Kratom in Substance Use Disorders. Current Addiction Reports 10:2, pages 304-316.
Crossref
Crossref
Nurul Atiqahd Muhamad Fauzi, Mei Lan Tan, Shahrul Bariyah Sahul Hamid, Darshan Singh & Mohammad Farris Iman Leong Bin Abdullah. (2022) Regular Kratom (Mitragyna speciosa Korth.) Use and Its Association With Endoplasmic Reticulum Stress Response. Journal of Addiction Medicine 16:6, pages e374-e381.
Crossref
Crossref
David A. Gorelick. (2022) Kratom: Substance of Abuse or Therapeutic Plant?. Psychiatric Clinics of North America 45:3, pages 415-430.
Crossref
Crossref
Wanumaidah Saengmolee, Rattanaphon Chaisaen, Phairot Autthasan, Chutimon Rungsilp, Nusaib Sa-Ih, Dania Cheaha, Ekkasit Kumarnsit & Theerawit Wilaiprasitporn. (2022) Consumer-Grade Brain Measuring Sensor in People With Long-Term Kratom Consumption. IEEE Sensors Journal 22:6, pages 6088-6097.
Crossref
Crossref
Kirsten E. Smith, Jeffrey M. Rogers, Kelly E. Dunn, Oliver Grundmann, Christopher R. McCurdy, Destiny Schriefer & David H. Epstein. (2022) Searching for a Signal: Self-Reported Kratom Dose-Effect Relationships Among a Sample of US Adults With Regular Kratom Use Histories. Frontiers in Pharmacology 13.
Crossref
Crossref
Inna Larsen, Emily Zhang & Pantea Farahmand. (2022) Current Understanding of the Effects and Potential Clinical Utility of Kratom: A Review. Journal of Psychiatric Practice 28:2, pages 92-97.
Crossref
Crossref
Norsyifa Harun, Nur Azzalia Kamaruzaman, Zarif Mohamed Sofian & Zurina Hassan. (2022) Mini review: Potential therapeutic values of mitragynine as an opioid substitution therapy. Neuroscience Letters 773, pages 136500.
Crossref
Crossref
Jack E. Henningfield, Daniel W. Wang & Marilyn A. Huestis. (2022) Kratom Abuse Potential 2021: An Updated Eight Factor Analysis. Frontiers in Pharmacology 12.
Crossref
Crossref
Nurul H.M. Yusoff, Zurina Hassan, Vikneswaran Murugaiyah & Christian P. Müller. (2022) The effect of mitragynine on extracellular activity of brain dopamine and its metabolites. Brain Research Bulletin 178, pages 1-8.
Crossref
Crossref
Takato Hiranita, Samuel Obeng, Abhisheak Sharma, Jenny L. Wilkerson, Christopher R. McCurdy & Lance R. McMahon. 2022. Behavioral Pharmacology of Drug Abuse: Current Status. Behavioral Pharmacology of Drug Abuse: Current Status
35
76
.
Shaun L. Greene. 2022. Novel Psychoactive Substances. Novel Psychoactive Substances
495
532
.
Elisabeth Prevete, Kim Paula Colette Kuypers, Eef Lien Theunissen, Ornella Corazza, Giuseppe Bersani & Johannes Gerardus Ramaekers. (2021) A systematic review of (pre)clinical studies on the therapeutic potential and safety profile of kratom in humans. Human Psychopharmacology: Clinical and Experimental 37:1.
Crossref
Crossref
Jeremy Y. Ng, Muhammad Ans & Amn Marwaha. (2021) Assessing the quality of information provided on websites selling Kratom (Mitragyna speciosa) to consumers in Canada. Substance Abuse Treatment, Prevention, and Policy 16:1.
Crossref
Crossref
Illa S. Johari, Norsyifa Harun, Zarif M. Sofian & Mohammed Shoaib. (2021) Pentylenetetrazol-like stimulus is not produced following naloxone-precipitated mitragynine withdrawal in rats. Psychopharmacology 238:11, pages 3183-3191.
Crossref
Crossref
Kirsten E. Smith, Jeffrey M. Rogers, Destiny Schriefer & Oliver Grundmann. (2021) Therapeutic benefit with caveats?: Analyzing social media data to understand the complexities of kratom use. Drug and Alcohol Dependence 226, pages 108879.
Crossref
Crossref
Walter C. Prozialeck, Peter C. Lamar, Michael KruppIIII, Matthew Moon, Laura E. Phelps & Oliver Grundmann. (2021) Kratom Use Within the Context of the Evolving Opioid Crisis and the COVID-19 Pandemic in the United States. Frontiers in Pharmacology 12.
Crossref
Crossref
Rahimah Hassan, Sasidharan Sreenivasan, Christian P. Müller & Zurina Hassan. (2021) Methadone, Buprenorphine, and Clonidine Attenuate Mitragynine Withdrawal in Rats. Frontiers in Pharmacology 12.
Crossref
Crossref
Elisabeth Müller, Thomas Hillemacher & Christian P. Müller. (2021) Kratom use for depression/anxiety self-management: challenges during the COVID-19 pandemic – A case report. Heliyon 7:5, pages e07039.
Crossref
Crossref
Alessandro E. Vento, Simone de Persis, Sergio De Filippis, Fabrizio Schifano, Flavia Napoletano, John M. Corkery & Georgios D. Kotzalidis. (2021) Case Report: Treatment of Kratom Use Disorder With a Classical Tricyclic Antidepressant. Frontiers in Psychiatry 12.
Crossref
Crossref
Mohammad Farris Iman Leong Bin Abdullah. (2020) Kratom Dependence and Treatment Options: A Comprehensive Review of the Literature. Current Drug Targets 21:15, pages 1566-1579.
Crossref
Crossref
Antonio Metastasio, Elisabeth Prevete, Darshan Singh, Oliver Grundmann, Walter C. Prozialeck, Charles Veltri, Giuseppe Bersani & Ornella Corazza. (2020) Can Kratom (Mitragyna speciosa) Alleviate COVID-19 Pain? A Case Study. Frontiers in Psychiatry 11.
Crossref
Crossref
Pietro Brunetti, Alfredo Fabrizio Lo Faro, Anastasio Tini, Francesco Paolo Busardò & Jeremy Carlier. (2020) Pharmacology of Herbal Sexual Enhancers: A Review of Psychiatric and Neurological Adverse Effects. Pharmaceuticals 13:10, pages 309.
Crossref
Crossref
Elisabeth Müller, Thomas Hillemacher & Christian P. Müller. (2020) Kratom instrumentalization for severe pain self-treatment resulting in addiction – A case report of acute and chronic subjective effects. Heliyon 6:7, pages e04507.
Crossref
Crossref
Steven C. Eastlack, Elyse M. Cornett & Alan D. Kaye. (2020) Kratom—Pharmacology, Clinical Implications, and Outlook: A Comprehensive Review. Pain and Therapy 9:1, pages 55-69.
Crossref
Crossref
Rahimah Hassan, Cheah Pike See, Sasidharan Sreenivasan, Sharif M. Mansor, Christian P. Müller & Zurina Hassan. (2020) Mitragynine Attenuates Morphine Withdrawal Effects in Rats—A Comparison With Methadone and Buprenorphine. Frontiers in Psychiatry 11.
Crossref
Crossref
Rebecca S. Williams & Dmitriy Nikitin. (2020) The internet market for Kratom, an opioid alternative and variably legal recreational drug. International Journal of Drug Policy 78, pages 102715.
Crossref
Crossref
Darshan Singh, Nelson Jeng Yeou Chear, Suresh Narayanan, Francisco Leon, Abhisheak Sharma, Christopher R. McCurdy, Bonnie A. Avery & Vicknasingam Balasingam. (2020) Patterns and reasons for kratom (Mitragyna speciosa) use among current and former opioid poly-drug users. Journal of Ethnopharmacology 249, pages 112462.
Crossref
Crossref
C Michael White. (2019) Pharmacologic and clinical assessment of kratom: An update. American Journal of Health-System Pharmacy 76:23, pages 1915-1925.
Crossref
Crossref
Jessica A. Nicewonder, Amy F. Buros, Charles A. Veltri & Oliver Grundmann. (2019) Distinct kratom user populations across the United States: A regional analysis based on an online survey. Human Psychopharmacology: Clinical and Experimental 34:5.
Crossref
Crossref
Hafez Mohammad Ammar Abdullah, Iqra Haq & Randall Lamfers. (2019) Cardiac arrest in a young healthy male patient secondary to kratom ingestion: is this ’legal high' substance more dangerous than initially thought ?. BMJ Case Reports 12:7, pages e229778.
Crossref
Crossref